Methodological Considerations in the Bioequivalence Assessment of Recombinant Human Serum Albumin [Letter]
Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-3
DOI: 10.2147/dddt.s639670 ↗Kurz gefasst
Leserbrief in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Peng Chang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, People's Republic of China.
ORCID-Profile: Danfeng Shen
Zitieren
APA
Chang, P., & Shen, D. (2026). Methodological Considerations in the Bioequivalence Assessment of Recombinant Human Serum Albumin [Letter]. Drug Design, Development and Therapy, Volume 20, 1-3. https://doi.org/10.2147/dddt.s639670
Vancouver
Chang P, Shen D. Methodological Considerations in the Bioequivalence Assessment of Recombinant Human Serum Albumin [Letter]. Drug Design, Development and Therapy. 2026;Volume 20:1-3. doi:10.2147/dddt.s639670
BibTeX
@article{Chang2026,
author = {Chang, Peng and Shen, Danfeng},
title = {Methodological Considerations in the Bioequivalence Assessment of Recombinant Human Serum Albumin [Letter]},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--3},
doi = {10.2147/dddt.s639670}
}
EUVIMED